JP2012504563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504563A5 JP2012504563A5 JP2011529471A JP2011529471A JP2012504563A5 JP 2012504563 A5 JP2012504563 A5 JP 2012504563A5 JP 2011529471 A JP2011529471 A JP 2011529471A JP 2011529471 A JP2011529471 A JP 2011529471A JP 2012504563 A5 JP2012504563 A5 JP 2012504563A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 241000272478 Aquila Species 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- -1 SRL172 Substances 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 108010017271 denileukin diftitox Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005831 male reproductive organ cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 229940100027 ontak Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 229950010550 resiquimod Drugs 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08017305.7 | 2008-10-01 | ||
| EP20080017305 EP2172211B1 (en) | 2008-10-01 | 2008-10-01 | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| US10597008P | 2008-10-16 | 2008-10-16 | |
| US61/105,970 | 2008-10-16 | ||
| PCT/EP2009/006979 WO2010037513A1 (en) | 2008-10-01 | 2009-09-28 | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504563A JP2012504563A (ja) | 2012-02-23 |
| JP2012504563A5 true JP2012504563A5 (enExample) | 2013-06-20 |
| JP5753783B2 JP5753783B2 (ja) | 2015-07-22 |
Family
ID=40342382
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529471A Expired - Fee Related JP5753783B2 (ja) | 2008-10-01 | 2009-09-28 | 神経膠芽細胞腫（ｇｂｍ）およびその他の癌の治療に用いる腫瘍関連ペプチド組成物と関連抗癌ワクチン |
| JP2011529472A Expired - Fee Related JP5855940B2 (ja) | 2008-10-01 | 2009-09-28 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2014126001A Expired - Fee Related JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2015200021A Active JP6150859B2 (ja) | 2008-10-01 | 2015-10-08 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016021002A Expired - Fee Related JP6214066B2 (ja) | 2008-10-01 | 2016-02-05 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136519A Expired - Fee Related JP6297632B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136518A Expired - Fee Related JP6294914B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136516A Pending JP2017029135A (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136517A Expired - Fee Related JP6294913B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136515A Expired - Fee Related JP6367266B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529472A Expired - Fee Related JP5855940B2 (ja) | 2008-10-01 | 2009-09-28 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2014126001A Expired - Fee Related JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2015200021A Active JP6150859B2 (ja) | 2008-10-01 | 2015-10-08 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016021002A Expired - Fee Related JP6214066B2 (ja) | 2008-10-01 | 2016-02-05 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136519A Expired - Fee Related JP6297632B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136518A Expired - Fee Related JP6294914B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136516A Pending JP2017029135A (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136517A Expired - Fee Related JP6294913B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136515A Expired - Fee Related JP6367266B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (19) | US8318677B2 (enExample) |
| EP (12) | EP2172211B1 (enExample) |
| JP (10) | JP5753783B2 (enExample) |
| KR (6) | KR102392070B1 (enExample) |
| CN (3) | CN102170900B (enExample) |
| AU (2) | AU2009300088B2 (enExample) |
| BR (2) | BRPI0920791B8 (enExample) |
| CA (9) | CA2936870C (enExample) |
| CY (11) | CY1116302T1 (enExample) |
| DK (12) | DK2172211T3 (enExample) |
| EA (3) | EA032437B1 (enExample) |
| ES (12) | ES2536465T3 (enExample) |
| HR (12) | HRP20201025T8 (enExample) |
| HU (11) | HUE031030T2 (enExample) |
| LT (10) | LT2172212T (enExample) |
| MX (3) | MX2011003540A (enExample) |
| NZ (4) | NZ591882A (enExample) |
| PL (12) | PL2172211T3 (enExample) |
| PT (12) | PT2172211E (enExample) |
| RS (12) | RS53782B1 (enExample) |
| SI (12) | SI2172211T1 (enExample) |
| TR (2) | TR201900852T4 (enExample) |
| UA (3) | UA125277C2 (enExample) |
| WO (2) | WO2010037514A2 (enExample) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| US7612162B2 (en) | 2004-09-21 | 2009-11-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response |
| AU2008281015B2 (en) * | 2007-07-27 | 2012-07-26 | Immatics Biotechnologies Gmbh | Novel immunotherapy against neuronal and brain tumors |
| SI2113253T1 (sl) | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| RS53782B1 (sr) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| SE535982C2 (sv) * | 2009-12-15 | 2013-03-19 | Theravac Pharmaceuticals Ab | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| DK2608799T3 (en) * | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
| US20140017266A1 (en) * | 2010-12-03 | 2014-01-16 | The Government Of The United States, As Represented By The Secretary Of Hhs, Nih | Anti-podoplanin antibodies and methods of use |
| KR20130126671A (ko) * | 2010-12-14 | 2013-11-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법 |
| US20140154269A1 (en) * | 2011-04-26 | 2014-06-05 | The Methodist Hospital Research Institute | Targeted nanovectors and their use for treatment of brain tumors |
| CN104023749B (zh) | 2011-09-14 | 2019-12-17 | 西北大学 | 能穿过血脑屏障的纳米缀合物 |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| CN110711188A (zh) | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN103372217B (zh) * | 2012-04-28 | 2014-12-10 | 中国科学院深圳先进技术研究院 | 聚合物纳米载体制剂及其制备方法和应用 |
| EP2849772A4 (en) * | 2012-05-16 | 2016-03-02 | Stemline Therapeutics Inc | TUMOR VACCINES TREATED AGAINST CANCER STEM CELLS |
| CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| TWI636065B (zh) * | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| PT3456339T (pt) | 2013-08-05 | 2021-12-09 | Immatics Biotechnologies Gmbh | Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| MX2019013161A (es) * | 2013-11-04 | 2020-02-03 | Immatics Biotechnologies Gmbh | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. |
| CN104698059B (zh) * | 2013-12-04 | 2017-07-21 | 苏州中赢医疗科技有限公司 | 一种脑胶质瘤肿瘤标志物及其应用 |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| RS60106B1 (sr) | 2014-04-25 | 2020-05-29 | Bluebird Bio Inc | Mnd promoterni himerni antigenski receptori |
| EP3134095B1 (en) | 2014-04-25 | 2020-04-22 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| JP6613526B2 (ja) * | 2014-05-28 | 2019-12-04 | 学校法人東京女子医科大学 | 膠芽腫の予測方法 |
| JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| CN111394317B (zh) | 2014-06-06 | 2024-07-12 | 2赛文缇生物公司 | 改善的t细胞组合物 |
| JP6366379B2 (ja) * | 2014-06-20 | 2018-08-01 | キヤノン株式会社 | 被検体情報取得装置 |
| US20170226216A1 (en) | 2014-07-24 | 2017-08-10 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| JP6474893B2 (ja) * | 2014-11-06 | 2019-02-27 | オーエスイー・イミュノセラピューティクス | 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法 |
| SG10202013144UA (en) | 2014-12-12 | 2021-02-25 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| KR102435015B1 (ko) * | 2014-12-23 | 2022-08-22 | 이매틱스 바이오테크놀로지스 게엠베하 | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| KR20240151873A (ko) | 2015-03-17 | 2024-10-18 | 이매틱스 바이오테크놀로지스 게엠베하 | 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합 |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CN107810193B (zh) * | 2015-05-06 | 2022-03-22 | 伊玛提克斯生物技术有限公司 | 用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| EP3307307A4 (en) | 2015-06-09 | 2019-05-01 | The Board of Regents of the University of Oklahoma | COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE |
| US11207405B2 (en) | 2015-06-24 | 2021-12-28 | Immodulon Therapeutics Limited | Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy |
| CN108026154B (zh) | 2015-07-01 | 2022-03-08 | 伊玛提克斯生物技术有限公司 | 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PE20180259A1 (es) * | 2015-07-06 | 2018-02-05 | Immatics Biotechnologies Gmbh | Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres |
| MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| TWI794761B (zh) | 2015-08-28 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| CN108289909A (zh) | 2015-10-19 | 2018-07-17 | 巴尔的摩马里兰大学 | 用于产生工程改造的人原代血液树突细胞系的方法 |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| HK1255541A1 (zh) * | 2015-12-11 | 2019-08-23 | Immatics Biotechnologies Gmbh | 用於多种癌症免疫治疗的新型肽和肽组合物 |
| SG11201804957VA (en) | 2015-12-16 | 2018-07-30 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| US10604759B2 (en) | 2016-01-15 | 2020-03-31 | City Of Hope | Targeting glioblastoma stem cells through the TLX-TET3 axis |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN105664134B (zh) * | 2016-03-13 | 2019-04-26 | 浙江药苑生物科技有限公司 | 一种用于治疗骨癌的药物组合物 |
| GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| HUE060725T2 (hu) | 2016-03-16 | 2023-04-28 | Immatics Biotechnologies Gmbh | Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| SG10202110335PA (en) * | 2016-04-06 | 2021-10-28 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2017194170A1 (en) * | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| KR101881300B1 (ko) | 2016-06-30 | 2018-07-25 | 영남대학교 산학협력단 | 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법 |
| CN110022889B (zh) * | 2016-10-03 | 2024-05-10 | 渥太华医院研究所 | 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法 |
| US12109234B2 (en) | 2016-11-04 | 2024-10-08 | 2Seventy Bio, Inc. | Anti-BCMA CAR T cell compositions |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| RU2725811C1 (ru) | 2017-01-06 | 2020-07-06 | Ютайлекс Ко., Лтд. | Антитела против 4-1bb человека и их применение |
| GB201702863D0 (en) * | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| US20180248175A1 (en) * | 2017-02-28 | 2018-08-30 | Lyten, Inc. | Mixed allotrope particulate carbon films and carbon fiber mats |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| CN107058596A (zh) * | 2017-06-19 | 2017-08-18 | 上海市第十人民医院 | 一种与恶性胶质瘤诊断相关的标志物及其应用 |
| CN107034305A (zh) * | 2017-06-19 | 2017-08-11 | 上海市第十人民医院 | 恶性胶质瘤的一种诊断标志物 |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
| EP3724327A4 (en) * | 2017-12-14 | 2022-01-12 | EZY Biotech LLC | SUBJECT-SPECIFIC TUMOR INHIBITION CELLS AND THEIR USE |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| ES2935702T3 (es) * | 2018-04-11 | 2023-03-09 | Enterome S A | Péptidos antigénicos para la prevención y el tratamiento del cáncer |
| CN108715832B (zh) * | 2018-06-01 | 2020-11-10 | 段海峰 | 一种抑制肿瘤生长的间充质干细胞及制备方法和应用 |
| JP2021530218A (ja) | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| WO2020110154A1 (en) * | 2018-11-30 | 2020-06-04 | Bharat Biotech International Limited | A chimeric therapeutic vaccine |
| RU2706554C1 (ru) * | 2018-12-13 | 2019-11-19 | Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ | Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов |
| CN109796536B (zh) * | 2019-02-22 | 2021-09-17 | 上海尚泰生物技术有限公司 | 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法 |
| AR118519A1 (es) | 2019-03-29 | 2021-10-20 | Intervet Int Bv | Estabilización de la bacteria mollicutes viva en una composición líquida |
| EP4600650A3 (en) | 2019-04-05 | 2025-11-26 | Earli Inc. | Improved methods and compositions for synthetic biomarkers |
| US10937541B2 (en) * | 2019-05-28 | 2021-03-02 | PAIGE.AI, Inc. | Systems and methods for processing images to prepare slides for processed images for digital pathology |
| JP7457733B2 (ja) | 2019-05-30 | 2024-03-28 | グリットストーン バイオ インコーポレイテッド | 改変アデノウイルス |
| CN110579457B (zh) * | 2019-09-20 | 2021-11-02 | 郑州大学第一附属医院 | 波形蛋白特异响应性荧光探针及其制备方法和应用 |
| CN112824427B (zh) * | 2019-11-18 | 2022-06-24 | 杨小骏 | 一种抑制胶质瘤的短肽及其应用 |
| IL294608A (en) * | 2020-01-10 | 2022-09-01 | Brigham & Womens Hospital Inc | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| CN115151268A (zh) * | 2020-02-24 | 2022-10-04 | 加利福尼亚大学董事会 | 使用脑特异性抗原归巢，阻断和向大脑提供基于细胞的治疗 |
| CN113318225B (zh) * | 2020-02-28 | 2024-01-19 | 无锡派列博生物医药科技有限公司 | 肿瘤免疫增强剂及其制法和应用 |
| CN113621025A (zh) * | 2020-03-18 | 2021-11-09 | 北京鼎成肽源生物技术有限公司 | 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用 |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| IL296947A (en) * | 2020-03-31 | 2022-12-01 | Walking Fish Therapeutics | Modified b cells and methods of use thereof |
| MX2022013208A (es) | 2020-05-12 | 2022-11-14 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| KR102711471B1 (ko) | 2020-08-14 | 2024-09-30 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| EP4203994A4 (en) * | 2020-08-28 | 2024-07-03 | Torigen Pharmaceuticals, Inc. | Immune memory enhanced preparations and uses thereof |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| WO2022192457A1 (en) * | 2021-03-09 | 2022-09-15 | Bostongene Corporation | Predicting response to treatments in patients with clear cell renal cell carcinoma |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2023192820A2 (en) * | 2022-03-30 | 2023-10-05 | Iogenetics, Llc | Tumor-associated antigens in brain tumors |
| PL441229A1 (pl) * | 2022-05-19 | 2023-11-20 | Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk | Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych |
| CN120272531B (zh) * | 2025-06-10 | 2025-08-19 | 鼐济医药科技(杭州)有限公司 | 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5338839A (en) * | 1988-04-12 | 1994-08-16 | Massachusetts Institute Of Technology | DNA encoding nestin protein |
| GB2267257A (en) | 1992-05-14 | 1993-12-01 | Ford Motor Co | A vehicle load compartment liner. |
| KR100235089B1 (en) | 1992-05-14 | 1999-12-15 | Mitsui Chemicals Inc | Ptp or blister packaging articles and packaging material therefor |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| IL120561A0 (en) * | 1996-04-24 | 1997-07-13 | Akzo Nobel Nv | Peptides suitable for use in immunosuppressive therapy |
| EP0942748A4 (en) * | 1996-07-22 | 2004-12-08 | Univ Rockefeller | ENV-GLYCOPROTEIN VACCINE FOR PROTECTION AGAINST HTLV-I AND HTLV-II INFECTIONS |
| WO1998031797A1 (en) | 1997-01-15 | 1998-07-23 | Zymogenetics, Inc. | Zppar6, human tailless nuclear hormone receptor (tlx receptor) |
| EP0910641A1 (en) * | 1997-02-13 | 1999-04-28 | Smithkline Beecham Plc | Neural cell adhesion molecule splicing variants |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| WO1999028349A2 (en) * | 1997-12-02 | 1999-06-10 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
| US7258860B2 (en) * | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20070004655A9 (en) * | 1998-04-27 | 2007-01-04 | Murphy Gerald P | Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| US20030082586A1 (en) * | 1999-06-29 | 2003-05-01 | Millennium Pharmaceuticals, Inc. | Antibodies having diagnostic, preventive, therapeutic, and other uses |
| CA2392757A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences Inc. | Nucleic acids, proteins, and antibodies |
| US20030139327A9 (en) * | 2000-01-31 | 2003-07-24 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| WO2002020036A1 (de) * | 2000-09-06 | 2002-03-14 | Mueller Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| AU2002226030A1 (en) * | 2000-12-04 | 2002-06-18 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2002046767A2 (en) * | 2000-12-08 | 2002-06-13 | Oxford Glycosciences (Uk) Ltd. | Diagnosis and treatment of alzheimer's disease |
| AU2002254482A1 (en) * | 2001-03-19 | 2002-10-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| CA2364106A1 (fr) * | 2001-11-30 | 2003-05-30 | Christopher Gillberg | Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques |
| US6589642B1 (en) | 2001-12-21 | 2003-07-08 | Kloeckner Pentaplast Of America, Inc. | Three part high moisture barrier for packages |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| US20030223994A1 (en) | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
| AU2003258134A1 (en) * | 2002-08-09 | 2004-02-25 | Applera Corporation | Lung cancer target proteins and use thereof |
| JP4721633B2 (ja) * | 2002-10-11 | 2011-07-13 | 財団法人癌研究会 | 血小板凝集促進活性を有する物質 |
| WO2004067029A1 (fr) * | 2002-12-27 | 2004-08-12 | Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. | Procede de preparation d'un vaccin et vaccins antitumoraux |
| JP2006522156A (ja) | 2003-04-04 | 2006-09-28 | ファーマサイクリックス，インコーポレイテッド | サフィリンおよびその使用 |
| US7273980B2 (en) | 2004-01-13 | 2007-09-25 | Wardle Scott A | Position and velocity transducer using a phonograph disc and turntable |
| CA2554195C (en) * | 2004-01-23 | 2011-02-22 | Green Peptide Co., Ltd. | Peptide originating in epidermal growth factor receptor (egfr) |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20080280317A1 (en) * | 2004-08-27 | 2008-11-13 | Northeastern University | Comprehensive Characterization Of Complex Proteins At Trace Levels |
| SI1642905T1 (sl) * | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop |
| WO2006062094A1 (ja) * | 2004-12-07 | 2006-06-15 | Toray Industries, Inc. | 新規癌抗原ペプチド及びその用途 |
| KR100809410B1 (ko) * | 2005-07-06 | 2008-03-05 | 주식회사 브레인가드 | 줄기세포 분화 유도용 조성물 및 그의 용도 |
| PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| ATE461215T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| WO2007047796A2 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| WO2007072494A1 (en) | 2005-12-23 | 2007-06-28 | Naik Praful Ramchandra | Metallized packaging blister container |
| CA2665816C (en) * | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| CA2700573C (en) * | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008109757A2 (en) * | 2007-03-06 | 2008-09-12 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
| US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
| KR101184869B1 (ko) | 2008-04-24 | 2012-09-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형 |
| SI2113253T1 (sl) * | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| RS53782B1 (sr) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| KR102311038B1 (ko) * | 2014-05-28 | 2021-10-07 | 노노 인코포레이티드 | Tat-nr2b9c의 클로라이드 염 |
| PE20181897A1 (es) | 2016-04-21 | 2018-12-11 | Immatics Biotechnologies Gmbh | Inmunoterapia contra el melanoma y otros tipos de cancer |
| EP3679065A4 (en) * | 2017-09-06 | 2021-05-19 | California Institute of Technology | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) |
-
2008
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
-
2009
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko active Active
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko active Active
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
-
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
-
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
-
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
-
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja active Active
-
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
-
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
-
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
-
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
-
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
-
2021
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504563A5 (enExample) | ||
| HRP20170115T1 (hr) | Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma | |
| JP2010534627A5 (enExample) | ||
| JP2013530157A5 (enExample) | ||
| CA3021114C (en) | Use of the lipidated immune response modifier compound n-4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxy}butly)octadecanamide | |
| ES2573456T3 (es) | Vectores adenovirales quiméricos y ARNbc como agonista de TLR3 | |
| ES2628744T3 (es) | Métodos y productos para inducir inmunidad en mucosas | |
| RU2583004C2 (ru) | Композиция для лечения рака предстательной железы | |
| Hedayat et al. | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases | |
| ES2380796T3 (es) | Oligonucleótidos inmunoestimuladores y sus usos. | |
| US9352028B2 (en) | Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC) | |
| JP2018522822A5 (enExample) | ||
| JP2016195616A5 (enExample) | ||
| AU2008265911B2 (en) | Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens | |
| JP2013536240A5 (enExample) | ||
| JP2013536157A5 (enExample) | ||
| JP2014521687A5 (enExample) | ||
| CA2915904A1 (en) | Composition and vaccine for treating prostate cancer | |
| WO2012117257A8 (en) | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer | |
| NZ576423A (en) | Novel Formulations of Tumour-Associated Peptides Binding to Human Leukocyte Antigen (HLA) Class I or II Molecules for Vaccines | |
| JP2010507361A (ja) | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 | |
| ES2993567T3 (en) | Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19) | |
| JP2013508415A5 (enExample) | ||
| Seo et al. | Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation | |
| Xiang et al. | Promising particle-based vaccines in cancer therapy |